ADC Therapeutics

We were honored to join the Lymphoma Research Foundation and the dedicated researchers, healthcare providers, patients, caregivers and advocates that make up the #lymphoma community in support of the advancements made in lymphoma research and patient care made possible by their efforts.   Together, through continued collaboration, we move closer to our shared goal: advancing care for those impacted by this disease.

#18ICML: We’re excited to share updated data from the investigator-initiated trial evaluating our CD19-targeted ADC for the treatment of r/r marginal zone lymphoma (#MZL) at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. Learn more: https://xmrrwallet.com/cmx.plnkd.in/erYxGEkU

Today, we announced updated results from our LOTIS-7 Phase 1b trial evaluating our CD19-targeted ADC in combination with a bispecific antibody to treat relapsed/refractory (r/r) diffuse large B-cell lymphoma (#DLBCL). These data will be presented at #EHA2025 in Milan, Italy, highlighting the safety and efficacy of this novel combination therapy. Read more: https://xmrrwallet.com/cmx.plnkd.in/e6MB58cE Join us today at 8:00 a.m. ET for a live webcast and conference call featuring LOTIS-7 trial principal investigator and #EHA2025 presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. Our management team will also provide corporate updates. Register here: https://xmrrwallet.com/cmx.plnkd.in/ejvQJakf

We’re pleased to welcome Tim Coughlin, CPA, to our board of directors. Mr. Coughlin brings more than two decades of financial and strategic leadership in biotech, notably serving as CFO of a biopharmaceutical company through the discovery, development and approval of key therapies.

A huge thank you to Tim Gillum, Executive Director, Strategic Operations & Continuous Improvement, Technical Operations, and an #ADCTValuesInAction award winner! 👏 Your commitment to accountability has made a lasting impact across the organization and on #TeamADCT members. Congratulations, Tim, and thank you for your outstanding work!

We’re proud to recognize Jeffrey Pinsky, Associate Director, Commercial Operations, as an #ADCTValuesInAction award winner! 🎉 Jeff consistently demonstrates integrity in all that he does and is a reflection of our core values. Congratulations, Jeff, and thank you for your dedication and leadership! #TeamADCT #ValuesInAction

Congratulations to this round’s #ADCTValuesInAction award winners! 🎉 We’re proud to recognize Marie Carpunky, Senior Manager, Quality Systems, for exemplifying true collaboration. Thank you, Marie, for consistently going above and beyond to support your colleagues and drive our shared success. #TeamADCT #ValuesInAction

 Today, our CEO Ameet Mallik is participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference at 10:30 a.m. ET. A #webcast will be available via the Events & Presentations page in the Investors section of our website, ir.adctherapeutics.com. #RBCHealthcare

Today, we announced our first quarter 2025 financial results and provided operational updates. https://xmrrwallet.com/cmx.plnkd.in/etS_-jgz

We're excited to share that abstracts on updated data from the LOTIS-7 Phase 1b trial evaluating our CD19-targeted #antibodydrugconjugate in combination with the bispecific antibody glofitamab to treat relapsed/refractory (r/r) diffuse large B-cell lymphoma (#DLBCL) have been accepted for presentation at #EHA2025 and #18ICML. Full presentation details here: https://xmrrwallet.com/cmx.plnkd.in/e9mEbv_h